What is the market size potential for Grail's multi-cancer early detection screening test?
Answered at 21:14 in Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing
What is the market size potential for Grail's multi-cancer early detection screening test?
Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally. Currently, only standardized tests exist for five types of cancer—breast, prostate, colon, cervical, and lung—while about 8% of cancer deaths occur from cancers without recommended screening.
Full answer and detailsRead the whole answer, key facts and every other question from this episode
In short
Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally.
Guest · Ensemble Capital Second Quarter 2024 Portfolio Update · Intrinsic Investing · answer at 21:14
Key takeaways
- Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally.
Quote to remember
“Either the largest companies in the world will gobble up a larger share of profits than has ever occurred in the U.S., or the average stock will perform much better than the S&P 500 in the years ahead, as the excessive outperformance of these mega cap stocks reverts, as it has in every past instance.”
The full answer · about 3 min
Grail's multi-cancer early detection screening (MCED) test could detect 50 different types of cancer from a single non-invasive blood drop across a market that could be as large as hundreds of millions of people globally. Currently, only standardized tests exist for five types of cancer—breast, prostate, colon, cervical, and lung—while about 8% of cancer deaths occur from cancers without recommended screening.
Key facts
- S&P 500 returned 15.3% in first half of 2024; Ensemble Capital strategy returned 8%
- Average stock in S&P 500 up only 5% in first half of 2024
- Magnificent Seven stocks up 94.9% over five-quarter period versus 16.2% for average stock
- NVIDIA up 345% over past five quarters; up 2,926% over past five years versus S&P 500 up 101%
- Five largest companies in S&P 500 make up 25% of entire index—most intense concentration in at least half a century
People, companies and topics mentioned
More answers from this episode
- 1:01Why did the S&P 500 return 15.3% in the first half of 2024 while the average stock in the index returned only 5%?
- 4:16How does NVIDIA's 345% five-quarter return compare to other Magnificent Seven stocks?
- 8:16What valuation multiples do mega-cap stocks trade at compared to the S&P 500 average?
- 9:01What percentage of S&P 500 stocks have outperformed the broader index in 2024?
- 18:58How much did Illumina's sequencing cost per human genome decline from 2010 to 2021?